Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy
- PMID: 23200539
- DOI: 10.1016/j.beha.2012.10.005
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy
Abstract
There is a need for improvements on the results of current therapies for patients with acute myelogenous leukemia (AML). A number of strategies are being used to achieve this goal. Here we present data that indicate that the addition of a histone deacetylase (HDAC) inhibitor, such as vorinostat, to idarubicin and cytarabine results in a very high response rate and can be safely administered to patients with leukemia. These results form the bases of the next SWOG front-line trial in AML. Here, we present the rationale for such combination and the studies that led to the support of this concept including both in vitro models and initial phase 1 trials.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.Am J Hematol. 2013 Nov;88(11):961-6. doi: 10.1002/ajh.23544. Epub 2013 Sep 9. Am J Hematol. 2013. PMID: 23877926 Free PMC article. Clinical Trial.
-
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.Medicine (Baltimore). 2020 Jun 12;99(24):e20094. doi: 10.1097/MD.0000000000020094. Medicine (Baltimore). 2020. PMID: 32541448 Free PMC article.
-
[Diagnostic image (92). A man with fever during chemotherapy. Invasive pulmonary mycosis].Ned Tijdschr Geneeskd. 2002 Jun 15;146(24):1126. Ned Tijdschr Geneeskd. 2002. PMID: 12092303 Dutch.
-
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.Expert Opin Investig Drugs. 2011 Feb;20(2):287-95. doi: 10.1517/13543784.2011.542750. Epub 2010 Dec 31. Expert Opin Investig Drugs. 2011. PMID: 21192773 Review.
-
Panobinostat for the treatment of acute myelogenous leukemia.Expert Opin Investig Drugs. 2016 Sep;25(9):1117-31. doi: 10.1080/13543784.2016.1216971. Epub 2016 Aug 8. Expert Opin Investig Drugs. 2016. PMID: 27485472 Review.
Cited by
-
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.Cancer. 2017 Dec 15;123(24):4851-4859. doi: 10.1002/cncr.30949. Epub 2017 Aug 25. Cancer. 2017. PMID: 28841236 Free PMC article. Clinical Trial.
-
Digging deep into "dirty" drugs - modulation of the methylation machinery.Drug Metab Rev. 2015 May;47(2):252-79. doi: 10.3109/03602532.2014.995379. Epub 2015 Jan 8. Drug Metab Rev. 2015. PMID: 25566693 Free PMC article. Review.
-
Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy.Leukemia. 2014 Mar;28(3):577-88. doi: 10.1038/leu.2013.264. Epub 2013 Sep 12. Leukemia. 2014. PMID: 24080946 Free PMC article.
-
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Blood. 2014 Jan 23;123(4):554-61. doi: 10.1182/blood-2013-09-527044. Epub 2013 Dec 5. Blood. 2014. PMID: 24311721 Free PMC article.
-
Knockdown of eukaryotic translation initiation factor 3 subunit D (eIF3D) inhibits proliferation of acute myeloid leukemia cells.Mol Cell Biochem. 2018 Jan;438(1-2):191-198. doi: 10.1007/s11010-017-3127-5. Epub 2017 Aug 12. Mol Cell Biochem. 2018. PMID: 28801778
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical